Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 3;10(64):6879-6884.
doi: 10.18632/oncotarget.27347.

Expression of matrix metalloproteinase 2 and 9 in breast cancer and breast fibroadenoma: a randomized, double-blind study

Luana Mota Martins  1 , Carla Solange de Melo Escorcio Dourado  1 , Larysse Maira Campos-Verdes  1 , Fabiane Araújo Sampaio  1 , Camila Maria Simplício Revoredo  1 , Danylo Rafhael Costa-Silva  1 , Maria da Conceição Barros-Oliveira  1 , Elmo de Jesus Nery Junior  1 , Lucia Maria do Rego-Medeiros  2 , Luiz Henrique Gebrim  1 , Francisco Adelton Alves-Ribeiro  1 , Gilmara Péres Rodrigues  1 , Diego Cipriano Chagas  1 , Dilina do Nascimento Marreiro  1 , Benedito Borges da Silva  1   2
Affiliations

Expression of matrix metalloproteinase 2 and 9 in breast cancer and breast fibroadenoma: a randomized, double-blind study

Luana Mota Martins et al. Oncotarget. .

Abstract

Background: Matrix metalloproteinases (MMPs) 2 and 9 may play an important role in cell proliferation and dissemination of cancer. However, few studies have compared the expression of these proteins between breast cancer and fibroadenoma.

Material and methods: A randomized, double-blind study was carried out in 66 premenopausal women, aged 20-49 years, who had been diagnosed with fibroadenoma or breast cancer. The patients were divided into two groups: Group A, control (fibroadenoma, n=36) and Group B, study (cancer, n=30). Immunohistochemical analysis was performed using tissue samples of fibroadenoma and breast cancer to assess MMP-2 and MMP-9 antigen expression. Cells were considered positive if exhibiting brown cytoplasmic staining. Fisher's exact test was used to compare the percentage of cases with cells expressing MMP-2 and MMP-9 in control and study groups (p < 0.05).

Results: Light microscopy showed a higher concentration of cells with positive cytoplasmic staining for MMP-2 and MMP-9 expression in breast cancer than in fibroadenoma. The percentage of cases with cells expressing MMP-2 in the control and study groups was 41.67% and 86.11%, respectively (p < 0.0009), whereas the percentage of cases with cells expressing MMP-9 in groups A and B was 66.67% and 93.33%, respectively (p<0.0138). MMP-2 and MMP-9 positive expression was significantly higher in moderately differentiated tumors compared to well and poorly differentiated tumors, p <0.005 and p<0.001, respectively.

Conclusions: The current study shows that MMP-2 and MMP-9 protein expression was significantly higher in the breast cancer than in the fibroadenoma and also in moderately differentiated breast cancer.

Keywords: breast neoplasms; fibroadenoma; immunohistochemistry; matrix metalloproteinase-2; matrix metalloproteinase-9.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST The authors have no conflict of interest.

Figures

Figure 1
Figure 1
Photomicrography of histological section of a portion of fibroadenoma and breast cancer, showing: (B, D) innumerous cells with strong brown-stained cytoplasm for MMP-2 and MMP-9 in the breast cancer group compared to sparse brown stained cytoplasm in the breast fibroadenoma group (A, C).
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: E359–86. 10.1002/ijc.29210. - DOI - PubMed
    1. Quintanilha LF, Souza LN, Sanches D, Demarco RS, Fukutani KF. The impact of cancer campaigns in Brazil: a Google Trends analysis. Ecancermedicalscience. 2019; 13: 963. 10.3332/ecancer.2019.963. - DOI - PMC - PubMed
    1. Anderson KN, Schwab RB, Martinez ME. Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat. 2014; 144:1–10. 10.1007/s10549-014-2852-7. - DOI - PMC - PubMed
    1. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, A’Hern R. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res. 2006; 12: 1024s–30s. 10.1158/1078-0432.CCR-05-2127. - DOI - PubMed
    1. Borges US, Costa-Silva DR, da Silva-Sampaio JP, Escórcio-Dourado CS, Conde AM Jr, Campelo V, Gebrim LH, da Silva BB, Lopes-Costa PV. A comparative study of Ki-67 antigen expression between luminal A and triple-negative subtypes of breast cancer. Med Oncol. 2017; 34: 156. 10.1007/s12032-017-1019-x. - DOI - PubMed